Clinic
H.B. Magruder Memorial Hospital
H.B. Magruder Memorial Hospital was paid $5.62M by Medicaid between Jan 2018 and Dec 2024, across 105 billing codes. Its largest line is 99283, emergency room visit (moderate) — 35% of everything it billed.
33Billing provider infoH.B. MAGRUDER MEMORIAL HOSPITAL
PORT CLINTON, OH 43452
PORT CLINTON, OH 43452
33aNPI1922079532assigned 01/31/2006
33bProvider typeUrgent Care Clinic/Center
28Total paid$5.62M
24GClaims130,858
24DCodes billed105
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Urgent Care Clinic/Center providers in Ohio
Rank by total paid#7 of 95
Median peer was paid$201K
This provider vs. median28×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 13,424 | $598K | |
| 2019 | 12,645 | $529K | |
| 2020 | 7,451 | $444K | |
| 2021 | 10,897 | $638K | |
| 2022 | 11,211 | $512K | |
| 2023 | 43,271 | $1.51M | |
| 2024incomplete | 31,959 | $1.39M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 35% | 22,878 | 14,521 | $1.96M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 17% | 17,573 | 11,678 | $978K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.3% | 5,056 | 3,589 | $522K |
| 96361 | Intravenous infusion, hydration; each additional hour | 9.3% | 1,636 | 1,041 | $521K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.3% | 3,497 | 830 | $183K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.3% | 2,187 | 1,642 | $130K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.2% | 371 | 304 | $121K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 2.1% | 1,395 | 338 | $119K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.0% | 1,048 | 780 | $115K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.9% | 391 | 331 | $104K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.8% | 991 | 613 | $101K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.6% | 306 | 239 | $88K |
93 more codes
| 99214 | Doctor's office visit, returning patient (more involved) | 1.3% | 982 | $72K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.3% | 225 | $71K |
| 80053 | Comprehensive metabolic panel | 1.0% | 7,312 | $58K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 606 | $56K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,497 | $49K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 190 | $32K |
| 97161 | <1% | 457 | $31K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 9,238 | $25K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 139 | $24K |
| G0378 | Hospital observation service, per hour | <1% | 374 | $23K |
| 80061 | Lipid panel | <1% | 897 | $18K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 347 | $16K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,101 | $16K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 158 | $14K |
| 36415 | Collection of venous blood by venipuncture | <1% | 12,259 | $14K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 68 | $12K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,430 | $11K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,087 | $10K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,084 | $10K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 231 | $8K |
| 87428 | <1% | 301 | $8K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 124 | $7K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,280 | $5K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 106 | $5K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 443 | $5K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 156 | $4K |
| 84439 | <1% | 182 | $4K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 91 | $4K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 977 | $4K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,283 | $3K |
| 87070 | <1% | 1,390 | $3K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 12 | $3K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 31 | $3K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,555 | $3K |
| 83735 | <1% | 1,710 | $3K | |
| 71045 | Radiologic examination, chest; single view | <1% | 768 | $3K |
| 84484 | <1% | 1,737 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 753 | $2K |
| 97116 | <1% | 53 | $2K | |
| 83605 | <1% | 999 | $2K | |
| 99406 | <1% | 99 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 199 | $2K |
| 87077 | <1% | 487 | $2K | |
| 82607 | <1% | 77 | $2K | |
| 87186 | <1% | 484 | $2K | |
| Q3014 | Telehealth originating site facility fee | <1% | 37 | $2K |
| 83880 | <1% | 685 | $1K | |
| 81001 | <1% | 1,434 | $1K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,383 | $1K |
| 81003 | <1% | 862 | $1K | |
| 83540 | <1% | 108 | $1K | |
| 96376 | <1% | 375 | $1K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 126 | $1K |
| 85610 | <1% | 926 | $985.79 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 883 | $952.05 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 106 | $827.61 |
| 85652 | <1% | 123 | $789.84 | |
| 83690 | <1% | 951 | $558.53 | |
| 86140 | <1% | 120 | $530.48 | |
| 80306 | <1% | 498 | $490.86 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,744 | $291.00 |
| 81025 | <1% | 646 | $266.36 | |
| 87040 | <1% | 148 | $251.14 | |
| 73030 | <1% | 13 | $219.81 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 59 | $201.05 |
| 82570 | <1% | 26 | $196.28 | |
| 82728 | <1% | 14 | $172.55 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 504 | $170.14 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 173 | $160.68 |
| 80320 | <1% | 212 | $152.81 | |
| 82043 | <1% | 13 | $89.61 | |
| 85379 | <1% | 297 | $78.98 | |
| 87205 | <1% | 46 | $69.08 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,240 | $47.97 |
| J2704 | Injection, propofol, 10 mg | <1% | 128 | $47.52 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 50 | $45.91 |
| 85730 | <1% | 90 | $38.10 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 251 | $36.89 |
| 01992 | <1% | 67 | $26.48 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 114 | $26.24 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,226 | $23.93 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 192 | $23.44 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 133 | $16.18 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 37 | $13.41 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 180 | $8.35 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 86 | $7.42 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 42 | $0.83 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 51 | $0.12 |
| 86738 | 0% | 19 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 17 | $0.00 |
| 80329 | 0% | 70 | $0.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 31 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMARSICO, NICK (PRESIDENT/CEO)